Search results for: Antibiotics
Filter search results
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
…and projecting public health: Spectrum value: Enables use of narrow-spectrum antibiotics by identifying specific pathogens and resistance patterns. Transmission value: Reduces the spread of infectious and resistant pathogens through earlier detection and…
OHE’s submission for the DHSC’s next 10 years of planning
9 December 2024
…implications. The UK is a world leader in novel incentive models of payment – NICE and NHS England’s pioneering trial of the ‘subscription’ model for antibiotics, has the potential to…
Cystic Fibrosis
1 March 1986
…25 years. The reasons for this improvement reflect a consortium of factors: earlier diagnosis, the availability and appropriate use of effective antibiotics and improved patterns of health care. They have…
Antibacterials: Roundtable Addresses the Critical Issues
10 November 2011
…raised included the danger of stewardship being a screen for anticompetitive behavior, the need to include generics, and the possibility of a tax on newly-generic antibiotics to raise funds for…
Spotlight on OHE: Adaptive Pathways, Economic Evaluation, Stated Preferences and Life-cycle Price Modelling
5 November 2014
…to look closely at models of health economic evaluation in France, Germany and the UK. This presentation can be watched here https://www.youtube.com/watch?v=AyoScR9BjuU, from 00:29:27 to 1:28:00. Antibiotics and the…
OHE at HTAi 2017: Meet the Team
13 June 2017
…wide-spreading medical threat. Challenges include finding a balance between the need (i) for newly discovered and cost effective therapies and (ii) for good stewardship to preserve new antibiotics and slow…
OHE at HTAi 2018
29 May 2018
…10:45 AM – 12:00 PM, Cypress 1 (Level 2)] This session will explore how the benefits of antibiotics can best be captured in HTA, and how we should pay for…
Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?
17 September 2020
…announced a pilot programme of a ‘volume-delinked’ payment scheme, which will include a modified assessment approach of antibiotics. 6 It should be noted that NICE has no experience so far of assessing…
CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation
14 September 2021
…scientific risk, commercial risk can vary across therapeutic areas. In areas, like antibiotics, scientific understanding is relatively high but there is a commercial risk that health systems will not be…